UNIVERSITY OF THE SCIENCES IN PHILADELPHIA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1821-01-01
- Employees
- 612
- Market Cap
- -
- Website
- http://www.usciences.edu
Sling Therapeutics Launches with $35M Series A Financing to Develop Oral Small Molecule for Thyroid Eye Disease
Sling Therapeutics, Inc. has officially launched with a $35M Series A financing led by TPG's The Rise Fund, aiming to develop linsitinib, an oral small molecule for treating Thyroid Eye Disease (TED). The company has received FDA IND clearance and is preparing to initiate a Phase 2b clinical trial. Linsitinib, designed to inhibit the IGF-1R signaling pathway, offers a potential convenient oral treatment option for TED patients, aiming to reduce the treatment burden significantly.
© Copyright 2025. All Rights Reserved by MedPath